KYTHERA Biopharmaceuticals (FRA:KYT) Ending Cash Position : €82.25 Mil (As of Jun. 2015)

View and export this data going back to . Start your Free Trial

What is KYTHERA Biopharmaceuticals Ending Cash Position?

KYTHERA Biopharmaceuticals's Ending Cash Position for the quarter that ended in Jun. 2015 was €82.25 Mil.

KYTHERA Biopharmaceuticals's quarterly Ending Cash Position increased from Dec. 2014 (€23.70 Mil) to Mar. 2015 (€153.26 Mil) but then declined from Mar. 2015 (€153.26 Mil) to Jun. 2015 (€82.25 Mil).

KYTHERA Biopharmaceuticals's annual Ending Cash Position increased from Dec. 2012 (€60.44 Mil) to Dec. 2013 (€81.41 Mil) but then declined from Dec. 2013 (€81.41 Mil) to Dec. 2014 (€23.70 Mil).

KYTHERA Biopharmaceuticals Ending Cash Position Historical Data

The historical data trend for KYTHERA Biopharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KYTHERA Biopharmaceuticals Ending Cash Position Chart

KYTHERA Biopharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Ending Cash Position

16.39

26.28

60.44

81.41

23.70

KYTHERA Biopharmaceuticals Quarterly Data
	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15
Ending Cash Position	Get a 7-Day Free Trial														61.54	30.84	23.70	153.26	82.25

KYTHERA Biopharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

KYTHERA Biopharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2014 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	90.441	+	-66.739
	=	23.70

KYTHERA Biopharmaceuticals's Ending Cash Position for the quarter that ended in Jun. 2015 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	147.79	+	-65.54
	=	82.25

KYTHERA Biopharmaceuticals Ending Cash Position Related Terms

Thank you for viewing the detailed overview of KYTHERA Biopharmaceuticals's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

KYTHERA Biopharmaceuticals (FRA:KYT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » KYTHERA Biopharmaceuticals Inc (FRA:KYT) » Definitions » Ending Cash Position

Traded in Other Exchanges

N/A

Address

Website

http://www.kytherabiopharma.com

KYTHERA Biopharmaceuticals Inc was incorporated in Delaware in June 2004 under the name Dermion, Inc. It commenced operations in August 2005, and it changed its name to AESTHERx, Inc. In July 2006, it changed its name to KYTHERA Biopharmaceuticals, Inc. It is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The Company's objective is to develop first-in-class, prescription aesthetic products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. The Company's initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. The Company's product candidate, ATX-101, is a potential first-in-class, injectable drug in late stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. Based on clinical trials conducted to date, ATX-101 has exhibited significant, meaningful and long-lasting results in the reduction of submental fat.

KYTHERA Biopharmaceuticals (FRA:KYT) Headlines

No Headlines